临床试验中低血糖定义的重新界定:验证美国糖尿病协会/欧洲糖尿病研究协会近期采纳的定义
该研究事后分析SWITCH 1(n=501,1型糖尿病)、SWITCH 2(n=721,2型糖尿病)和DEVOTE(n=7,637,2型糖尿病)试验,比较ADA 2005定义与IHSG 2级低血糖定义。结果显示IHSG 2级定义能区分基础胰岛素治疗差异,推荐监管机构统一采用。
要点
- IHSG 2级定义(血糖<3.0 mmol/L,不依赖症状)在临床试验中得到验证。
- 该定义能区分德谷胰岛素与甘精胰岛素100 units/mL的低血糖差异。
- 推荐监管机构统一采纳IHSG 2级定义作为临床试验终点。
核心结论
- IHSG 2级低血糖定义在系列临床试验中得到验证,能区分基础胰岛素间的低血糖差异,推荐监管机构统一采用并用于未来临床试验。
研究设计与样本
- 对SWITCH 1(n=501,1型糖尿病)、SWITCH 2(n=721,2型糖尿病)和DEVOTE(n=7,637,2型糖尿病)试验进行事后分析,患者随机接受德谷胰岛素或甘精胰岛素100 units/mL。
主要发现
- 在SWITCH 2中,低血糖事件估计率比随PG水平降低至3.0 mmol/L时治疗差异增大,之后未再观察额外治疗差异。
- SWITCH 1中观察到类似结果。
- 在SWITCH 2中,IHSG 2级定义产生的率比低于ADA 2005定义。
关键数值与推荐
- ADA 2005定义:PG确认≤3.9 mmol/L伴症状。
- IHSG 2级定义:PG确认<3.0 mmol/L,不依赖症状。
临床怎么用
- 未来临床试验可采用IHSG 2级定义作为低血糖终点,以更好区分基础胰岛素治疗差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine if the International Hypoglycaemia Study Group (IHSG) level 2 low glucose definition can identify clinically relevant hypoglycemia in clinical trials and offer value as an end point for future trials. RESEARCH DESIGN AND METHODS: A post hoc analysis was performed of the SWITCH (SWITCH 1: n = 501, type 1 diabetes; SWITCH 2: n = 721, type 2 diabetes) and DEVOTE (n = 7,637, type 2 diabetes) trials utilizing the IHSG low glucose definitions. Patients in all trials were randomized to either insulin degludec or insulin glargine 100 units/mL. In the main analysis, the following definitions were compared: 1) American Diabetes Association (ADA) 2005 (plasma glucose [PG] confirmed ≤3.9 mmol/L with symptoms); and 2) IHSG level 2 (PG confirmed <3.0 mmol/L, independent of symptoms). RESULTS: In SWITCH 2, the estimated rate ratios of hypoglycemic events indicated increasing differences between treatments with decreasing PG levels until 3.0 mmol/L, following which no additional treatment differences were observed. Similar results were observed for the SWITCH 1 trial. In SWITCH 2, the IHSG level 2 definition produced a rate ratio that was lower than the ADA 2005 definition. CONCLUSIONS: The IHSG level 2 definition was validated in a series of clinical trials, demonstrating its ability to discriminate between basal insulins. This definition is therefore recommended to be uniformly adopted by regulatory bodies and used in future clinical trials.
引用
- Heller SR, Buse JB, Ratner R, et al. Redefining Hypoglycemia in Clinical Trials: Validation of Definitions Recently Adopted by the American Diabetes Association/European Association for the Study of Diabetes. Diabetes Care. 2019. PMID: 31658975. doi:10.2337/dc18-2361
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。